DrugPatentWatch Database Preview
Drugs in Development Information for ND0612
» See Plans and Pricing
What is the drug development status for ND0612?
ND0612 is an investigational drug.
There have been 9 clinical trials for ND0612.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 28th 2019.
The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are NeuroDerm Ltd., Quotient Clinical, and Michael J. Fox Foundation for Parkinson's Research.
There are fifteen US patents protecting this investigational drug and one hundred and thirty-six international patents.
Summary for ND0612
| US Patents | 15 |
| International Patents | 136 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 58 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-08-28) |
| Vendors | 2 |
Recent Clinical Trials for ND0612
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless). | NeuroDerm Ltd. | Phase 3 |
| A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations | NeuroDerm Ltd. | Phase 3 |
| A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease | NeuroDerm Ltd. | Phase 2 |
Clinical Trial Summary for ND0612
Top disease conditions for ND0612
Top clinical trial sponsors for ND0612
US Patents for ND0612
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ND0612 | Start Trial | Dopa decarboxylase inhibitor compositions | NeuroDerm, Ltd. (Rehovot, IL) | Start Trial |
| ND0612 | Start Trial | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof | LobSor Pharmaceuticals Aktiebolag (Knivsta, SE) | Start Trial |
| ND0612 | Start Trial | Anti-nausea drug combinations | Start Trial | |
| ND0612 | Start Trial | Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same | Samyang Biopharmaceutical Corporation (Seoul, KR) | Start Trial |
| ND0612 | Start Trial | Sealing arrangement for syringe | AbbVie Inc. (North Chicago, IL) | Start Trial |
| ND0612 | Start Trial | DOPA decarboxylase inhibitor compositions | NeuroDerm, Ltd. (Rehovot, IL) | Start Trial |
| ND0612 | Start Trial | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor | LobSor Pharmaceuticals Aktiebolag (Knivsta, SE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ND0612
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ND0612 | Australia | AU2015228369 | 2034-03-13 | Start Trial |
| ND0612 | Canada | CA2942244 | 2034-03-13 | Start Trial |
| ND0612 | China | CN106413754 | 2034-03-13 | Start Trial |
| ND0612 | European Patent Office | EP3116475 | 2034-03-13 | Start Trial |
| ND0612 | Israel | IL247668 | 2034-03-13 | Start Trial |
| ND0612 | Japan | JP2017507973 | 2034-03-13 | Start Trial |
| ND0612 | Japan | JP2020011977 | 2034-03-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
